Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial

Clinical Trials

Volumn 10, Issue 2, 2013, Pages 292-299

  Dew, Alexander ^a   Khan, Seema ^a   Babinski, Christie ^a   Michel, Nancy ^a   Heffernan, Marie ^a   Stephan, Stefanie ^a   Jordan, Neil ^a   Jovanovic, Borko ^a   Carney, Paula ^a   Bergan, Raymond ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; ARTICLE; BREAST CANCER; CANCER PREVENTION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COST; COST EFFECTIVENESS ANALYSIS; HUMAN; PATIENT REFERRAL; PRIORITY JOURNAL; RECRUITMENT STRATEGY COST;

ADULT; AGED; BREAST NEOPLASMS; CHICAGO; CLINICAL TRIALS, PHASE II AS TOPIC; CONTINENTAL POPULATION GROUPS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MARKETING OF HEALTH SERVICES; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876524761     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512471452     Document Type: Article

References (21)

1. Bruner DW, Jones M, Buchanan D, Russo J. Reducing cancer disparities for minorities: A multidisciplinary research agenda to improve patient access to health systems, clinical trials, and effective cancer therapy. J Clin Oncol. 2006 ; 24: 2209-15
2. Duda C, Mahon I, Chen MH, et al. Impact and costs of targeted recruitment of minorities to the National Lung Screening Trial. Clin Trials. 2011 ; 8: 214-23
3. HowladerNNooneAMKrapchoM. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/ csr/1975-2008/(based on November 2010 SEER data submission, posted to SEER web site, 2011) (accessed 1 April 2011).
4. Taylor AL, Adams-Campbell LL, Wright JT. Risk/ benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?. J Natl Cancer Inst. 1999 ; 91: 1792-93
5. Swanson GM, Bailar JC. Selection and description of cancer clinical trials participants - Science or happenstance?. Cancer. 2002 ; 95: 950-59
6. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review. Cancer. 2008 ; 112: 228-42
7. Paskett ED, Reeves KW, McLaughlin JM, et al. Recruitment of minority and underserved populations in the United States: The Centers for Population Health and Health Disparities experience. Contemp Clin Trials. 2008 ; 29: 847-61
8. Lerman C, Rimer BK, Daly M, et al. Recruiting high risk women into a breast cancer health promotion trial. Cancer Epidemiol Biomarkers Prev. 1994 ; 3: 271-76
9. Grann VR, Jacobson JS, Troxel AB, et al. Barriers to minority participation in breast carcinoma prevention trials. Cancer. 2005 ; 104: 374-79
10. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA. 2004 ; 291: 2720-26
11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 ; 90: 1371-88
12. Bjornson-Benson WM, Stibolt TB, Manske KA, et al. Monitoring recruitment effectiveness and cost in a clinical trial. Control Clin Trials. 1993 ; 14: 52S - 67S
13. Cook ED, Moody-Thomas S, Anderson KB, et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials. 2005 ; 2: 436-42
14. Xu L, Wang SS, Healey MA, et al. The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research. ; 2011 ; 2011. 616.
15. Cook ED, Arnold KB, Hermos JA, et al. Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial. Clin Trials. 2010 ; 7: 90-99
16. Khan SA, Chatterton RT, Michel N, et al. Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase II trial. Cancer Prev Res. 2012 ; 5: 309-19
17. Drummond M, O'Brein BJ, Stoddart G, Torrance GW Methods for the Economic Evaluation of Health Care Programs. New York: Oxford University Press ; 2001 :
18. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007 ; 99: 1782-92
19. Valanis B, Blank J, Glass A. Mailing strategies and costs of recruiting heavy smokers in CARET, a large chemoprevention trial. Control Clin Trials. 1998 ; 19: 25-38
20. Robinson JL, Fuerch JH, Winiewicz DD, et al. Cost effectiveness of recruitment methods in an obesity prevention trial for young children. Prev Med. 2007 ; 44: 499-503
21. Gren L, Broski K, Childs J, et al. Recruitment methods employed in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Clin Trials. 2009 ; 6: 52-59